Thirdly, blockade of the cisplatin-induced TIMP-1 release by inhibitors of MAPK signalling pathways likewise conferred a reversal of the inhibitory impact of CM from cisplatin-treated lung cancer cells. Here, TIMP1 is linked to lung carcinoma.